Omalizumab for the Treatment of Multiple Food Allergies
New England Journal of Medicine2024Vol. 390(10), pp. 889–899
Citations Over TimeTop 1% of 2024 papers
Robert A. Wood, Alkis Togias, Scott H. Sicherer, Wayne G. Shreffler, Edwin Kim, Stacie M. Jones, Donald Y.M. Leung, Brian P. Vickery, J. Andrew Bird, Jonathan M. Spergel, Ahmar Iqbal, Julie Olsson, Monica Ligueros‐Saylan, Alkaz Uddin, Agustin Calatroni, Charmaine Huckabee, Nicole H. Rogers, Nancy A. Yovetich, Jennifer Dantzer, Kim Mudd, Julie Wang, Marion Groetch, David M. Pyle, Corinne Keet, Michael D. Kulis, Sayantani Sindher, Andrew Long, Amy M. Scurlock, Bruce J. Lanser, Tricia Lee, Christopher Parrish, Terri Brown‐Whitehorn, Amanda K. Rudman Spergel, Maria Veri, Sanaz Daneshfar Hamrah, Erica Brittain, Julian Poyser, Lisa M. Wheatley, R. Sharon Chinthrajah
Abstract
In persons as young as 1 year of age with multiple food allergies, omalizumab treatment for 16 weeks was superior to placebo in increasing the reaction threshold for peanut and other common food allergens. (Funded by the National Institute of Allergy and Infectious Diseases and others; ClinicalTrials.gov number, NCT03881696.).
Related Papers
- → Safety of a peanut oral immunotherapy protocol in children with peanut allergy(2009)268 cited
- → Update on peanut allergy: Prevention and immunotherapy(2018)16 cited
- → Safety and effectiveness of peanut oral immunotherapy in children under 12 months(2023)3 cited
- → Early age peanut oral immunotherapy is safe and effective at achieving desensitization in 27 pediatric patients with peanut allergy(2024)1 cited
- → Quality of Life and Improving Outcomes in Peanut Oral Immunotherapy(2022)